Navigation Links
TargetScan Evaluation is Shown to Deliver Potentially Higher Cancer Detection Rate and More Accurate Assessment of Grade
Date:11/24/2008

ST. LOUIS, Nov. 24 /PRNewswire/ -- A study released recently in the British Journal of Urology detailed the results from biopsies of 140 men who received care at Washington University in St. Louis, Duke University, and the University of Michigan. The study, titled "Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer," found that TargetScan(R) template guided biopsy technology potentially produces a higher cancer detection rate and more accurate assessment of grade.

The TargetScan system combines 3-D image acquisition with a stationary probe, which helps physicians plan and execute targeted prostate biopsies through accurate needle placement within a template, which in turn, can provide confidence in identifying locations of significant cancer in the prostate.

"As physicians we are challenged to provide accurate diagnosis and define the true extent of the disease so we don't over or underestimate the significance of the cancer," said Dr. Gerald Andriole, Professor and Chief of Urology at Washington University in St Louis School of Medicine, a member of the multi-center team that conducted the evaluation of TargetScan. The study's lead author, Dr. Adam Kibel, also from Washington University, agrees. "This technology allows physicians to accurately biopsy the prostate since the location of each biopsy is calculated on the basis of the prostate's size and shape. This may allow us to more accurately find and define the disease. This may allow better monitoring of patients on active surveillance. Importantly, since the location of each biopsy site is recorded, re-biopsy or treatments can be performed with more precision."

TargetScan Touch(TM) is the most current system based on the TargetScan technology platform. TargetScan Touch was unveiled recently at the 2008 American Society for Therapeutic Radiology and Oncology annual meeting, and has been tested at several of the nation's leading medical centers.

TargetScan technology is developed by Envisioneering Medical Technologies in St. Louis, under the guidance of physicians at Washington University in St. Louis. "Traditional hand-manipulated devices allow the prostate gland to shift, which impedes accurate biopsy and placement accuracy. By stabilizing the prostate, physicians can now detect cancer with greater confidence," said Robert Mills, president, Envisioneering Medical Technologies.

About Envisioneering Medical Technologies

Envisioneering Medical Technologies, based in St. Louis, Mo., is dedicated to creating the standard for prostate cancer care by developing technology for improving prostate cancer diagnosis and treatment precision and effectively managing patients throughout the continuum of care. For more information please visit http://www.envisioneeringmedical.com.

KM-0022 A


'/>"/>
SOURCE Envisioneering Medical Technologies
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bartlett Communications Launches Free Website Evaluation Tool for Small to Mid-Sized Businesses
2. Care Improvement Plus Achieves Top Scores for First SNP Evaluation Measures
3. Best Practice Database Provides Key Findings for Biopharma Product Launch Evaluation
4. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
5. VA Announces Expansion of Disability Evaluation System Pilot
6. DIA/FDA/PhRMA Drug Safety Conference: Planning the Lifecycle of Safety Evaluation
7. Study sees need for standardized evaluation of antibody response to HIV-1
8. Hooper Holmes Announces Sale of Claims Evaluation Division
9. Syntermed licenses Emory imaging technology for improved evaluation of heart failure patients
10. Dartmouth-Hitchcock Medical Center Evaluation Findings Demonstrate Masimo Patient SafetyNet(TM) Delivers Improvements in Clinical Outcomes and Patient Safety on General Care Floors
11. Population Health Impact Institute Releases Methods Evaluation Process(TM) (MEP(TM)) Accreditation Standards for Public Comment Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology: